- Home
- CHSCO vs ZLAB Comparison
CHSCO vs ZLAB Comparison
Compare CHSCO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHSCO
- ZLAB
- Stock Information
- Founded
- CHSCO N/A
- ZLAB 2013
- Country
- CHSCO United States
- ZLAB Cayman Islands
- Employees
- CHSCO N/A
- ZLAB 1869
- Industry
- CHSCO Farming/Seeds/Milling
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- CHSCO Industrials
- ZLAB Health Care
- Exchange
- CHSCO Nasdaq
- ZLAB Nasdaq
- Market Cap
- CHSCO N/A
- ZLAB 3.5B
- IPO Year
- CHSCO N/A
- ZLAB 2017
- Fundamental
- Price
- CHSCO $26.17
- ZLAB $32.28
- Analyst Decision
- CHSCO
- ZLAB Buy
- Analyst Count
- CHSCO 0
- ZLAB 4
- Target Price
- CHSCO N/A
- ZLAB $47.37
- AVG Volume (30 Days)
- CHSCO N/A
- ZLAB 1.6M
- Earning Date
- CHSCO N/A
- ZLAB 05-08-2025
- Dividend Yield
- CHSCO N/A
- ZLAB N/A
- EPS Growth
- CHSCO N/A
- ZLAB N/A
- EPS
- CHSCO N/A
- ZLAB N/A
- Revenue
- CHSCO N/A
- ZLAB $398,988,000.00
- Revenue This Year
- CHSCO N/A
- ZLAB $45.57
- Revenue Next Year
- CHSCO N/A
- ZLAB $47.91
- P/E Ratio
- CHSCO N/A
- ZLAB N/A
- Revenue Growth
- CHSCO N/A
- ZLAB 49.59
- 52 Week Low
- CHSCO N/A
- ZLAB $14.48
- 52 Week High
- CHSCO N/A
- ZLAB $39.77
- Technical
- Relative Strength Index (RSI)
- CHSCO 51.71
- ZLAB 50.28
- Support Level
- CHSCO $25.97
- ZLAB $28.34
- Resistance Level
- CHSCO $26.27
- ZLAB $33.45
- Average True Range (ATR)
- CHSCO 0.27
- ZLAB 2.30
- MACD
- CHSCO 0.04
- ZLAB -0.07
- Stochastic Oscillator
- CHSCO 87.32
- ZLAB 56.14
About CHSCO CHS Inc. Class B Cumulative Redeemable Preferred Stock
CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.